CY1110901T1 - Στερεοϊσομερεις ενωσεις και μεθοδοι για την αγωγη γαστρεντερικων διαταραχων και διαταραχων του κεντρικου νευρικου συστηματος - Google Patents
Στερεοϊσομερεις ενωσεις και μεθοδοι για την αγωγη γαστρεντερικων διαταραχων και διαταραχων του κεντρικου νευρικου συστηματοςInfo
- Publication number
- CY1110901T1 CY1110901T1 CY20101100615T CY101100615T CY1110901T1 CY 1110901 T1 CY1110901 T1 CY 1110901T1 CY 20101100615 T CY20101100615 T CY 20101100615T CY 101100615 T CY101100615 T CY 101100615T CY 1110901 T1 CY1110901 T1 CY 1110901T1
- Authority
- CY
- Cyprus
- Prior art keywords
- disorders
- compounds
- nervous system
- central nervous
- stereofficial
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 208000018522 Gastrointestinal disease Diseases 0.000 title abstract 2
- 210000003169 central nervous system Anatomy 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 208000035475 disorder Diseases 0.000 title 1
- 206010021518 Impaired gastric emptying Diseases 0.000 abstract 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 abstract 1
- 208000001288 gastroparesis Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/94—Oxygen atom, e.g. piperidine N-oxide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07D451/06—Oxygen atoms
- C07D451/10—Oxygen atoms acylated by aliphatic or araliphatic carboxylic acids, e.g. atropine, scopolamine
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Otolaryngology (AREA)
- Nutrition Science (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Fats And Perfumes (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53489204P | 2004-01-07 | 2004-01-07 | |
| US56093804P | 2004-04-09 | 2004-04-09 | |
| EP05705267A EP1704146B1 (en) | 2004-01-07 | 2005-01-07 | Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1110901T1 true CY1110901T1 (el) | 2015-06-10 |
Family
ID=34798839
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20101100615T CY1110901T1 (el) | 2004-01-07 | 2010-07-05 | Στερεοϊσομερεις ενωσεις και μεθοδοι για την αγωγη γαστρεντερικων διαταραχων και διαταραχων του κεντρικου νευρικου συστηματος |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US7176218B2 (enExample) |
| EP (2) | EP1704146B1 (enExample) |
| JP (2) | JP5200288B2 (enExample) |
| KR (1) | KR101240464B1 (enExample) |
| CN (1) | CN101824033B (enExample) |
| AT (1) | ATE464308T1 (enExample) |
| AU (2) | AU2005205531B2 (enExample) |
| BR (1) | BRPI0506736B1 (enExample) |
| CA (1) | CA2551686C (enExample) |
| CY (1) | CY1110901T1 (enExample) |
| DE (1) | DE602005020580D1 (enExample) |
| DK (2) | DK1704146T3 (enExample) |
| ES (2) | ES2344568T3 (enExample) |
| IL (1) | IL176569A (enExample) |
| MX (1) | MXPA06007853A (enExample) |
| NO (1) | NO337741B1 (enExample) |
| PT (2) | PT1704146E (enExample) |
| RU (1) | RU2374244C2 (enExample) |
| WO (1) | WO2005068461A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0211230D0 (en) | 2002-05-16 | 2002-06-26 | Medinnova Sf | Treatment of heart failure |
| US8524736B2 (en) | 2004-01-07 | 2013-09-03 | Armetheon, Inc. | Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders |
| US8138204B2 (en) * | 2004-01-07 | 2012-03-20 | Aryx Therapeutics, Inc. | Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders |
| DE602005020580D1 (de) * | 2004-01-07 | 2010-05-27 | Aryx Therapeutics | Stereoisomere verbindungen und verfahren zur behandlung von erkrankungen des magen-darm-trakts und des zentralen nervensystems |
| MY150958A (en) | 2005-06-16 | 2014-03-31 | Astrazeneca Ab | Compounds for the treatment of multi-drug resistant bacterial infections |
| CN101258151B (zh) * | 2005-08-31 | 2012-10-10 | ARYx医疗有限公司 | 用于治疗胃肠系统和中枢神经系统疾病的立体异构化合物的合成方法及中间体 |
| RU2418798C2 (ru) * | 2005-08-31 | 2011-05-20 | Арикс Терапьютикс, Инк. | Способы синтеза и промежуточные соединения при синтезе стереоизомерных соединений, пригодных для лечения желудочно-кишечных расстройств и расстройств центральной нервной системы |
| GB0525068D0 (en) | 2005-12-08 | 2006-01-18 | Novartis Ag | Organic compounds |
| US20080312291A1 (en) * | 2005-12-23 | 2008-12-18 | Udo Bauer | Heterocyclic Gaba-b Modulators |
| US20080085915A1 (en) * | 2006-06-23 | 2008-04-10 | Cyrus Becker | Compounds and methods for the treatment of gastrointestinal and central nervous system disorders |
| CN101402633A (zh) | 2007-09-11 | 2009-04-08 | 上海恒瑞医药有限公司 | 苯甲酰胺类衍生物、其制备方法及其在医药上的用途 |
| WO2010062959A1 (en) * | 2008-11-26 | 2010-06-03 | Aryx Therapeutics, Inc. | 5-ht4 receptor agonists for treating irritable bowel syndrome and colonic hypersensitivity |
| US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
| CN102762572A (zh) | 2010-02-01 | 2012-10-31 | 诺瓦提斯公司 | 作为CRF-1受体拮抗剂的吡唑并[5,1b]*唑衍生物 |
| WO2011092293A2 (en) | 2010-02-01 | 2011-08-04 | Novartis Ag | Cyclohexyl amide derivatives as crf receptor antagonists |
| US8835444B2 (en) | 2010-02-02 | 2014-09-16 | Novartis Ag | Cyclohexyl amide derivatives as CRF receptor antagonists |
| UY34094A (es) | 2011-05-27 | 2013-01-03 | Novartis Ag | Derivados de la piperidina 3-espirocíclica como agonistas de receptores de la ghrelina |
| PL395470A1 (pl) * | 2011-06-29 | 2013-01-07 | Adamed Spólka Z Ograniczona Odpowiedzialnoscia | Sulfonamidowe pochodne amin alicyklicznych do leczenia chorób osrodkowego ukladu nerwowego |
| EA201491990A1 (ru) | 2012-05-03 | 2015-02-27 | Новартис Аг | L-малатная соль 2,7-диазаспиро[4.5]дец-7-иловых производных и их кристаллические формы в качестве агонистов грелиновых рецепторов |
| BR112016024830A2 (pt) * | 2014-05-16 | 2017-08-15 | Raqualia Pharma Inc | receptor agonista 5-ht4 para gastroparesia |
| US10864367B2 (en) | 2015-02-24 | 2020-12-15 | Elira, Inc. | Methods for using an electrical dermal patch in a manner that reduces adverse patient reactions |
| US9956393B2 (en) | 2015-02-24 | 2018-05-01 | Elira, Inc. | Systems for increasing a delay in the gastric emptying time for a patient using a transcutaneous electro-dermal patch |
| US10335302B2 (en) | 2015-02-24 | 2019-07-02 | Elira, Inc. | Systems and methods for using transcutaneous electrical stimulation to enable dietary interventions |
| US10376145B2 (en) | 2015-02-24 | 2019-08-13 | Elira, Inc. | Systems and methods for enabling a patient to achieve a weight loss objective using an electrical dermal patch |
| EP3261712B1 (en) | 2015-02-24 | 2024-04-03 | Elira, Inc. | System for enabling appetite modulation and/or improving dietary compliance using an electro-dermal patch |
| US20220062621A1 (en) | 2015-02-24 | 2022-03-03 | Elira, Inc. | Electrical Stimulation-Based Weight Management System |
| US10765863B2 (en) | 2015-02-24 | 2020-09-08 | Elira, Inc. | Systems and methods for using a transcutaneous electrical stimulation device to deliver titrated therapy |
| US11495028B2 (en) * | 2018-09-28 | 2022-11-08 | Intel Corporation | Obstacle analyzer, vehicle control system, and methods thereof |
| US10570127B1 (en) * | 2018-11-05 | 2020-02-25 | Renexxion, Llc | Material and methods for the treatment of gastro-intestinal disorders |
| WO2020096911A1 (en) * | 2018-11-05 | 2020-05-14 | Renexxion, Llc | Methods of producing naronapride trihydrate |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) * | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) * | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| GB1425706A (en) | 1972-06-30 | 1976-02-18 | Wyeth John & Brother Ltd | Piperidine derivatives |
| US3916899A (en) * | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| CA1183847A (en) | 1981-10-01 | 1985-03-12 | Georges Van Daele | N-(3-hydroxy-4-piperidinyl)benzamide derivatives |
| US5057525A (en) * | 1981-10-01 | 1991-10-15 | Janssen Pharmaceutica N.V. | Novel N-(3-hydroxy-4-piperidinyl) benzamide derivatives |
| US5137896A (en) * | 1981-10-01 | 1992-08-11 | Janssen Pharmaceutica N.V. | N-(3-hydroxy-4-piperidinyl)benzamide derivatives |
| US4962115A (en) * | 1981-10-01 | 1990-10-09 | Janssen Pharmaceutica N.V. | Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives |
| GB8519707D0 (en) * | 1985-08-06 | 1985-09-11 | Fordonal Sa | Chemical compounds |
| US4870074A (en) * | 1986-04-30 | 1989-09-26 | Dainippon Pharmaceutical Co., Ltd. | Substituted benzamide derivatives, for enhancing gastrointestinal motility |
| NZ225152A (en) * | 1987-07-17 | 1990-04-26 | Janssen Pharmaceutica Nv | Heterocyclically substituted piperidinyl benzamides as pharmaceuticals |
| CA1317940C (en) | 1987-09-25 | 1993-05-18 | Georges H. P. Van Daele | Substituted n-(1-alkyl-3-hydroxy-4-piperidinyl)benzamides |
| US5041454A (en) * | 1987-09-25 | 1991-08-20 | Janssen Pharmaceutica N.V. | Novel substituted N-(1-alkyl-3-hydroxy-4-piperidinyl)benzamides |
| US4975439A (en) * | 1987-09-25 | 1990-12-04 | Janssen Pharmaceutical N.V. | Novel substituted N-(1-alkyl-3-hydroxy-4-piperidinyl)benzamides |
| JP3104142B2 (ja) * | 1991-02-15 | 2000-10-30 | 北陸製薬株式会社 | ベンズアミド誘導体 |
| TW243449B (enExample) * | 1991-02-15 | 1995-03-21 | Hokuriku Pharmaceutical | |
| US5395832A (en) * | 1991-02-15 | 1995-03-07 | Hokuriku Seiyaku Co., Ltd. | Benzamide derivatives |
| IT1260485B (it) * | 1992-05-29 | 1996-04-09 | Procedimento e dispositivo per il trattamento dell'obesita' di un paziente | |
| EP0651639A4 (en) * | 1992-07-07 | 1996-06-26 | Sepracor Inc | METHODS OF USING CISAPRIDE (+) FOR THE TREATMENT OF GASTROSOPHAGIC REFLUX AND OTHER DISORDERS. |
| CA2139638A1 (en) * | 1992-07-07 | 1994-01-20 | Nancy M. Gray | Methods of using (-) cisapride for the treatment of gastro-esophageal reflux disease and other disorders |
| US5705498A (en) | 1992-11-05 | 1998-01-06 | Smithkline Beecham Plc. | Piperidine derivatives as 5-HT4 receptor antagonists |
| US5472866A (en) * | 1992-12-24 | 1995-12-05 | Synaptic Pharmaceutical Corporation | DNA encoding 5-HT4A serotonin receptors |
| US5705798A (en) * | 1994-12-16 | 1998-01-06 | Mastercard International Inc. | System and method for processing a customized financial transaction card |
| US5712293A (en) * | 1995-06-07 | 1998-01-27 | Sepracor, Inc. | Methods for treating gastro-esophageal reflux disease and other disorders associated with the digestive tract using optically pure (-) norcisapride |
| US5739151A (en) * | 1996-07-19 | 1998-04-14 | Sepracor Inc. | Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride |
| US6147093A (en) * | 1996-07-19 | 2000-11-14 | Sepracor Inc. | Methods for treating gastroesophageal reflux disease |
| JP3529102B2 (ja) | 1997-07-11 | 2004-05-24 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノート シヤツプ | ５−ｈｔ３および５−ｈｔ４介在性障害に有用な（＋）−ノルシサプリド |
| JPH11292846A (ja) | 1998-02-10 | 1999-10-26 | Hokuriku Seiyaku Co Ltd | ベンズアミド誘導体及びそれを含有する医薬 |
| AR022338A1 (es) * | 1999-02-04 | 2002-09-04 | Hokuriku Pharmaceutical | Un compuesto de benzamida, medicamento que lo contiene, y uso para la manufactura de un medicamento para el tratamiento o prevencion de una enfermedad digestiva o para mejorar la movilidad del tracto gastrointestinal. |
| DE19933926A1 (de) | 1999-07-20 | 2001-01-25 | Boehringer Ingelheim Pharma | Biphenylderivate, ihre Herstellung und ihre Verwendung als Arzneimittel |
| US20040092511A1 (en) * | 1999-12-10 | 2004-05-13 | Billstein Stephan Anthony | Pharmaceutical combinations and their use in treating gastrointestinal and abdominal viscera disorders |
| AU2001264817A1 (en) | 2000-05-23 | 2001-12-17 | Exhale Therapeutics, Inc. | Method for treating respiratory disorders associated with pulmonary elastic fiber injury comprising the use of clycosaminoglycans |
| AU2001275326C1 (en) * | 2000-06-07 | 2006-09-21 | Aryx Therapeutics | Treatment of gastroesophageal reflux disease using piperidine derivatives |
| MXPA03000145A (es) * | 2002-01-07 | 2003-07-15 | Pfizer | Compuestos de oxo u oxi-piridina como moduladores de receptores 5-ht4. |
| DE602005020580D1 (de) * | 2004-01-07 | 2010-05-27 | Aryx Therapeutics | Stereoisomere verbindungen und verfahren zur behandlung von erkrankungen des magen-darm-trakts und des zentralen nervensystems |
-
2005
- 2005-01-07 DE DE602005020580T patent/DE602005020580D1/de not_active Expired - Lifetime
- 2005-01-07 MX MXPA06007853A patent/MXPA06007853A/es active IP Right Grant
- 2005-01-07 RU RU2006128589/04A patent/RU2374244C2/ru active
- 2005-01-07 KR KR1020067015208A patent/KR101240464B1/ko not_active Expired - Lifetime
- 2005-01-07 US US11/031,623 patent/US7176218B2/en not_active Expired - Lifetime
- 2005-01-07 ES ES05705267T patent/ES2344568T3/es not_active Expired - Lifetime
- 2005-01-07 AT AT05705267T patent/ATE464308T1/de active
- 2005-01-07 CA CA2551686A patent/CA2551686C/en not_active Expired - Lifetime
- 2005-01-07 PT PT05705267T patent/PT1704146E/pt unknown
- 2005-01-07 PT PT101530939T patent/PT2194053E/pt unknown
- 2005-01-07 JP JP2006549435A patent/JP5200288B2/ja not_active Expired - Lifetime
- 2005-01-07 EP EP05705267A patent/EP1704146B1/en not_active Expired - Lifetime
- 2005-01-07 EP EP10153093A patent/EP2194053B1/en not_active Expired - Lifetime
- 2005-01-07 CN CN2010101640045A patent/CN101824033B/zh not_active Expired - Lifetime
- 2005-01-07 WO PCT/US2005/000510 patent/WO2005068461A1/en not_active Ceased
- 2005-01-07 DK DK05705267.2T patent/DK1704146T3/da active
- 2005-01-07 AU AU2005205531A patent/AU2005205531B2/en not_active Expired
- 2005-01-07 ES ES10153093T patent/ES2415830T3/es not_active Expired - Lifetime
- 2005-01-07 BR BRPI0506736-7A patent/BRPI0506736B1/pt active IP Right Grant
- 2005-01-07 DK DK10153093.9T patent/DK2194053T3/da active
- 2005-03-23 US US11/087,167 patent/US7282509B2/en not_active Expired - Lifetime
-
2006
- 2006-06-26 IL IL176569A patent/IL176569A/en active IP Right Grant
- 2006-08-07 NO NO20063568A patent/NO337741B1/no unknown
-
2008
- 2008-11-13 AU AU2008243243A patent/AU2008243243B2/en not_active Expired
-
2010
- 2010-07-05 CY CY20101100615T patent/CY1110901T1/el unknown
-
2011
- 2011-11-30 JP JP2011261145A patent/JP5524939B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1110901T1 (el) | Στερεοϊσομερεις ενωσεις και μεθοδοι για την αγωγη γαστρεντερικων διαταραχων και διαταραχων του κεντρικου νευρικου συστηματος | |
| NO20081562L (no) | Syntetiske metoder og mellomprodukt for stereoisomeriske forbindelser som er nyttige for behandlingen av gastrointestinale og sentralnervesystemersykdommer | |
| BRPI0607017A2 (pt) | métodos e composições para o tratamento de condições relacionadas ao snc | |
| ATE507224T1 (de) | Verfahren und zwischenverbindungen zur herstellung von n4-phenyl-quinazolin-4-amin derivaten | |
| ATE450514T1 (de) | Piperazinylalkylpyrazol-derivate zur verwendung als selektive calciumkanalblocker des t-typs und verfahren zu ihrer herstellung | |
| ATE494890T1 (de) | Alpha-aminoamid-derivate zur behandlung von suchtstörungen | |
| ATE518846T1 (de) | 2-aminooxazolderivate als für die behandlung von schmerzen geeignete trpvl-antagonisten | |
| CR8696A (es) | Beta-carbolinas utiles para tratar enfermedades inflamatorias | |
| DE602004029616D1 (de) | Behandlung von neurologischen störungen mit hämatopoetischen wachstumsfaktoren | |
| NO20072060L (no) | 2-acylaminotiazolderivater | |
| ATE432930T1 (de) | Benzosulfonamide derivate, deren verfahren zum herstellung, und deren verwendung zur behandlung von schmerzen | |
| DE60333205D1 (de) | Histaminika zur behandlung von allergischer rhinitis | |
| MX2007016373A (es) | Compuestos de piridil y piridonil estereoisomericos y metodos para el tratamiento de trastornos gastrointestinales y del sistema nervioso central. | |
| DE602004023100D1 (de) | Verbindungen und verfahren zur behandlung von dyslipidemie | |
| ATE444749T1 (de) | Benzothiazolium verbindungen zur verwendung in methoden zur hemmung der no produktion und von tnf alpha und zur behandlung von coronavirus infektionen | |
| BRPI0509559A (pt) | compostos de pirazolamina para o tratamento de distúrbios neurodegenerativos | |
| ATE440836T1 (de) | Verbindungen | |
| WO2007098393A3 (en) | Compounds and methods for treating diseases with trpv4 channel receptors | |
| ATE555783T1 (de) | Mittel zur behandlung oder prävention von ischämischer neuropathie | |
| ATE520408T1 (de) | Zubereitung zur behandlung von mineralstoffmangel | |
| ATE473737T1 (de) | Verwendung von 2,3-dehydronaringenin-derivaten zur behandlung von entzündungsprozessen und diese derivate enthaltende pharmazeutische zusammensetzung | |
| DE602006017855D1 (de) | Verwendung von n-(dibenz (b,f)oxepin-10-ylmethyl)-n-methyl-n-prop-2-inylamin (omigapil) zur prophylaxe und/oder behandlung von muskeldystrophie | |
| CY1114088T1 (el) | Παραγωγα μεθοξυπιπεριδινης για να χρησιμοποιηθουν στην αγωγη γαστρεντερικων διαταραχων και διαταραχων του κεντρικου νευρικου συστηματος | |
| WO2004022041A3 (de) | Behandlung nicht allergischer rhinitis durch selektive phosphodiesterase 4-hemmstoffe | |
| TW200510363A (en) | Use of substituted chromans or thiocromans for the treatment of FGD |